216 related articles for article (PubMed ID: 11712411)
1. [Clinical difference between thiazolidinediones and biguanides].
Hotta N
Nihon Rinsho; 2001 Nov; 59(11):2219-27. PubMed ID: 11712411
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Kitaoka H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():464-9. PubMed ID: 12387035
[No Abstract] [Full Text] [Related]
3. [Combination therapy with biguanides].
Sakura H
Nihon Rinsho; 2002 Oct; 60 Suppl 10():724-8. PubMed ID: 12430309
[No Abstract] [Full Text] [Related]
4. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
5. [Insulin sensitizer drugs--review].
Yamanouchi T
Nihon Rinsho; 2002 Sep; 60 Suppl 9():409-15. PubMed ID: 12387026
[No Abstract] [Full Text] [Related]
6. [Clinical efficacy of Pioglitazone (AD-4833)].
Kaneko T; Baba S
Nihon Rinsho; 1997 Nov; 55 Suppl():142-6. PubMed ID: 9434458
[No Abstract] [Full Text] [Related]
7. Targeted glycemic control in type 2 diabetes.
Skyler JS
J Fla Med Assoc; 1998 Aug; 85(2):7-15. PubMed ID: 9782713
[No Abstract] [Full Text] [Related]
8. [Rosiglitazone (BRL-49653)].
Oka Y
Nihon Rinsho; 2002 Sep; 60 Suppl 9():438-41. PubMed ID: 12387030
[No Abstract] [Full Text] [Related]
9. Oral agents in the management of type 2 diabetes mellitus.
Luna B; Feinglos MN
Am Fam Physician; 2001 May; 63(9):1747-56. PubMed ID: 11352285
[TBL] [Abstract][Full Text] [Related]
10. Insulin sensitizers.
Zangeneh F; Kudva YC; Basu A
Mayo Clin Proc; 2003 Apr; 78(4):471-9. PubMed ID: 12683699
[TBL] [Abstract][Full Text] [Related]
11. [Against insulin resistance. Insulin sensitizers].
Verspohl EJ; Weiland F
Pharm Unserer Zeit; 2002; 31(3):280-92. PubMed ID: 12071125
[No Abstract] [Full Text] [Related]
12. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
Bressler R; Johnson DG
Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
[TBL] [Abstract][Full Text] [Related]
13. [Causal therapy of type 2 diabetes. Determining the cause of insulin resistance early].
MMW Fortschr Med; 2000 Nov; 142(47):56. PubMed ID: 11143782
[No Abstract] [Full Text] [Related]
14. Glitazones: clinical effects and molecular mechanisms.
Stumvoll M; Häring HU
Ann Med; 2002; 34(3):217-24. PubMed ID: 12173692
[TBL] [Abstract][Full Text] [Related]
15. Current treatment of insulin resistance in type 2 diabetes mellitus.
Tan MH
Int J Clin Pract Suppl; 2000 Oct; (113):54-62. PubMed ID: 11965833
[TBL] [Abstract][Full Text] [Related]
16. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.
Harrigan RA; Nathan MS; Beattie P
Ann Emerg Med; 2001 Jul; 38(1):68-78. PubMed ID: 11423816
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological treatment of type 2 diabetes.
Hermans MP; Buysschaert M
Acta Clin Belg; 2004; 59(2):59-66. PubMed ID: 15224468
[No Abstract] [Full Text] [Related]
18. Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.
Yokoyama I; Yonekura K; Moritan T; Tateno M; Momose T; Ohtomo K; Inoue Y; Nagai R
J Nucl Med; 2001 Jul; 42(7):1005-10. PubMed ID: 11438619
[TBL] [Abstract][Full Text] [Related]
19. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone.
Goldstein BJ
Int J Clin Pract; 2000 Jun; 54(5):333-7. PubMed ID: 10954962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
